Rockwell Medical, Inc. (RMTI) Set to Announce Earnings on Monday
Rockwell Medical, Inc. (NASDAQ:RMTI) will release its earnings data after the market closes on Monday, November 6th. Analysts expect Rockwell Medical to post earnings of ($0.10) per share for the quarter.
Rockwell Medical (NASDAQ:RMTI) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.04). Rockwell Medical had a negative return on equity of 42.22% and a negative net margin of 39.68%. The firm had revenue of $13.24 million during the quarter, compared to the consensus estimate of $13.05 million. During the same period in the prior year, the firm posted ($0.11) EPS. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. On average, analysts expect Rockwell Medical to post $-0.39 EPS for the current fiscal year and $-0.28 EPS for the next fiscal year.
Rockwell Medical, Inc. (NASDAQ RMTI) traded up 0.083% during mid-day trading on Monday, hitting $6.035. The stock had a trading volume of 56,638 shares. The firm’s market cap is $312.25 million. The stock has a 50 day moving average of $7.05 and a 200-day moving average of $7.22. Rockwell Medical, Inc. has a 1-year low of $3.55 and a 1-year high of $8.98.
TRADEMARK VIOLATION WARNING: “Rockwell Medical, Inc. (RMTI) Set to Announce Earnings on Monday” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/30/rockwell-medical-inc-rmti-set-to-announce-earnings-on-monday.html.
Several research firms have issued reports on RMTI. Zacks Investment Research raised Rockwell Medical from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Wednesday, October 25th. BidaskClub downgraded Rockwell Medical from a “sell” rating to a “strong sell” rating in a report on Saturday, August 5th. Finally, Ifs Securities began coverage on Rockwell Medical in a report on Monday, August 14th. They set a “strong-buy” rating and a $11.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $8.88.
Rockwell Medical Company Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.